Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabazitaxel versus prolonged infusional ifosfamide in pretreated dedifferentiated liposarcoma
NL-OMON42166Phase 2Withdrawn
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Jan 2015
- Modality
- Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in dedifferentiated liposarcoma (DDL) comparing Cabazitaxel with Prolonged infusional ifosfamide (2 arms). Primary endpoint: Progression-free survival at 12 weeks. Planned start Jan 2015; status: withdrawn.
02
Drugs
cabazitaxelifosfamide
03
Conditions
dedifferentiated liposarcoma (DDL)
Beyond the preview
Go deeper on NL-OMON42166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42166.